HOME CME/CE INFORMATION PROGRAM DIRECTORS NEWSLETTER ARCHIVE EDIT PROFILE RECOMMEND TO A COLLEAGUE eDiabetes Review VOLUME 2, ISSUE 2 BEYOND BASAL INSULIN: COMBINATION THERAPY WITH GLP-1 RAs
نویسنده
چکیده
In this issue we review recent publications describing: A meta-analysis of 15 trials investigating GLP-1 RAs in combination with basal insulin GLP-1 RA/basal insulin combinations across a wide range of insulin titration The efficacy and safety differences between short-acting (intermittent) versus longeracting (continuous) GLP-1 RAs in combination with basal insulin The effects on glycemic control, adverse events, and weight when combining basal insulin with GLP-1 RAs vs prandial insulin.
منابع مشابه
HOME CME/CE INFORMATION PROGRAM DIRECTORS NEWSLETTER ARCHIVE EDIT PROFILE RECOMMEND TO A COLLEAGUE eDiabetes Review VOLUME 2, ISSUE 10 RISKS AND BENEFITS OF SGLT-2 INHIBITOR AGENTS
Anne Peters, MD has indicated that she has been on the advisory board or consulted for Abbott Diabetes Care, Becton Dickinson, Bigfoot Biomedical, Biodel, Boehringer Ingelheim, CVS/Caremark, Eli Lilly and Company, Bristol-Myers Squibb/AstraZeneca, Intarcia, Merck, Janssen, Lexicon, Novo Nordisk, OptumRx, and Thermalin. She has received research grant funding from Janssen and Medtronic Foundatio...
متن کاملCombination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
Treatment algorithms for type 2 diabetes call for intensification of therapy over time as the disease progresses and glycaemic control worsens. If diet, exercise and oral antihyperglycaemic medications (OAMs) fail to maintain glycaemic control then basal insulin is added and ultimately prandial insulin may be required. However, such an intensification strategy carries risk of increased hypoglyc...
متن کاملFuture challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy
Most algorithms for type 2 diabetes mellitus (T2DM) do not recommend treatment escalation until glycated haemoglobin (HbA1c) fails to reach the recommended target of 7% (53 mmol/mol) within approximately 3 months on any treatment regimen ("treat to failure"). Clinical inertia and/or poor adherence to therapy contribute to patients not reaching glycaemic targets when managed according to this pa...
متن کاملCombination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
Glycemic control has been considered a major therapeutic goal within the scope of diabetes management, as supported by robust observational and experimental evidence. However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the importance that pharmacological treatment of type 2 diabetes mellitus provides not only glycemic ...
متن کاملResponse to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39(Suppl. 1):S52–S59
We thank Giugliano et al. (1) for their comments in this issue of Diabetes Care on the recommendations for insulin therapy in type 2 diabetes outlined in the American Diabetes Association’s Standards ofMedical Care in Diabetesd 2016 (2). We agree that after basal insulin failure, there are three treatment options: continuing basal insulin and adding a rapid-acting insulin analog before the larg...
متن کامل